Research Progress of Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as a New Potential Therapeutic Peptide in Diabetes and Its Complications

doi:10.13523/j.cb.20180108

China Biotechnology

2018, Vol. 38

Issue (1): 62-68 DOI: 10.13523/j.cb.20180108

Orginal Article

Research Progress of Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as a New Potential Therapeutic Peptide in Diabetes and Its Complications

Qiu-xia YAN^1,²,Yi MA¹(

),An HONG¹

1 Department of Cellular Biology of Jinan University, Institute of Biological Medicine of Jinan University, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China
2 Center for Reproductive Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan 511518,China;

Download:

HTML

PDF(706KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) belongs to the secretin, glucagon, and vasoactive intestinal peptide(VIP) family. PACAP is widely distributed in the brain and peripheral organs, notably in the endocrine pancreas, gonads, respiratory and urogenital tracts. PACAP play important roles in metabolism and neuroprotection. Diabetes is a common chronic metabolic disease characterized by high blood sugar. Its complications have become the main cause of mortality and disability in diabetes patients. The knowledge accumulated over the past years on the role of this neuropeptide in diabetes and its major complications, particularly emphasizing its potential for new therapeutic approaches were outlined.

Key words： Pituitary adenylate cyclase-activating polypeptide (PACAP) Diabetes mellitus Diabetic complications

Received: 12 July 2017 Published: 31 January 2018

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Qiu-xia YAN
	Yi MA
	An HONG

Cite this article:

Qiu-xia YAN,Yi MA,An HONG. Research Progress of Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) as a New Potential Therapeutic Peptide in Diabetes and Its Complications. China Biotechnology, 2018, 38(1): 62-68.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20180108 OR https://manu60.magtech.com.cn/biotech/Y2018/V38/I1/62

Fig.1 The Schematic representation of precursor and bioactive peptide of PACAP

Fig.2 PACAP is highly conservative in different species

Fig.3 Primary structure of PACAP38 indicating domains responsible for recognition, activation, and selectivity of the receptors inferred from structure-activity relationship studies


[1]	Miyata A,Arimura A,Dahl R R,et al.Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun, 1989, 164(1): 567-574. doi: 10.1016/0006-291X(89)91757-9

[2]	Guariguata L,Whiting D R, Hambleton I,et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract, 2014, 103(2): 137-149. doi: 10.1016/j.diabres.2013.11.002 pmid: 24630390

[3]	Vaudry D,Falluel A,Bourgault S,et al.Pituitary adenylate cyclase-activating polypeptide and its receptors:20 years after the discovery. Pharmacol Rev,2009, 61(3): 283-357. doi: 10.1124/pr.109.001370

[4]	Akesson L,Ahren B,Manganiello V C,et al.Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology,2003, 144(12): 5293-5299. doi: 10.1210/en.2003-0364 pmid: 12960103

[5]	Casanova L,Hughes F J,Preshaw P M.Diabetes and periodontal disease:a two-way relationship. Br Dent J,2014, 217(8): 433-437. doi: 10.1038/sj.bdj.2014.907 pmid: 25342350

[6]	Parker A,Meyer J,Lewitzky S,et al.A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes,2001, 50(3): 675-680. doi: 10.2337/diabetes.50.3.675 pmid: 11246890

[7]	Yada T,Sakurada M,Filipsson K,et al.Intraperitoneal PACAP administration decreases blood glucose in GK rats,and in normal and high fat diet mice. Ann N Y Acad Sci,2000, 921(12): 259-263. doi: 10.1111/j.1749-6632.2000.tb06974.x pmid: 11193831

[8]	Nakata M,Yada T.Physiological and therapeutic roles of PACAP in glucose metabolism and diabetes. Nihon Yakurigaku Zasshi,2004, 123(4): 267-273. doi: 10.1254/fpj.123.267 pmid: 15056942

[9]	Sakurai Y,Shintani N,Hayata A,et al.Trophic effects of PACAP on pancreatic islets:a mini-review. J Mol Neurosci,2011, 43(1): 3-7. doi: 10.1007/s12031-010-9424-z pmid: 20645023

[10]	Yamamoto K,Hashimoto H,Tomimoto S,et al.Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes,2003, 52(5): 1155-1162. doi: 10.2337/diabetes.52.5.1155

[11]	Gray S L,Cummings K J,Jirik F R,et al.Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. Mol Endocrinol,2001, 15(10): 1739-1747. doi: 10.1210/mend.15.10.0705 pmid: 11579206

[12]	Ahren B.Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. Neural Signaling:Opportunities for Novel Diagnostic Approaches and Therapies,2008, 1144(11): 28-35. doi: 10.1196/annals.1418.003 pmid: 19076360

[13]	Tsutsumi M,Claus T H,Liang Y,et al.A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes,2002, 51(5): 1453-1460. doi: 10.2337/diabetes.51.5.1453

[14]	Ma Y,Luo T J,Xu W N,et al.A new recombinant pituitary adenylate cyclase-activating peptide-derived peptide efficiently promotes glucose uptake and glucose-dependent insulin secretion. Acta Biochim Biophys Sin (Shanghai),2012, 44(11): 948-956. doi: 10.1093/abbs/gms078 pmid: 23052710

[15]	Ma Y,Ma M,Dai Y,et al.Expression, identification and biological effects of a novel VPAC2-specific agonist with high stability and bioactivity. Acta Biochim Biophys Sin (Shanghai),2010, 42(1): 21-29. doi: 10.1093/abbs/gmp106 pmid: 20043043

[16]	Ryu S,Ornoy A,Samuni A,et al.Oxidative stress in Cohen diabetic rat model by high-sucrose,low-copper diet:inducing pancreatic damage and diabetes. Metabolism,2008, 57(9): 1253-1261. doi: 10.1016/j.metabol.2008.04.021 pmid: 18702952

[17]	Castorina A,Giunta S,Mazzone V,et al.Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells. Peptides,2010, 31(12): 2276-2283. doi: 10.1016/j.peptides.2010.08.013 pmid: 20800633

[18]	St Hilaire R C,Murthy S N,Kadowitz P J,et al. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation. Peptides,2010, 31(8): 1517-1522. doi: 10.1016/j.peptides.2010.04.024 pmid: 20452385

[19]	Racz B,Gasz B,Borsiczky B,et al.Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol,2007, 153(1-3): 115-123. doi: 10.1016/j.ygcen.2006.12.006 pmid: 17270184

[20]	Mazzocchi G,Malendowicz L K,Neri G,et al.Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Int J Mol Med,2002, 9(3): 233-243. doi: 10.3892/ijmm.9.3.233 pmid: 11836629

[21]	Akesson L,Ahren B,Edgren G,et al.VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology,2005, 146(2): 744-750. doi: 10.1210/en.2004-0504

[22]	Zhang X Y,Wang N L,Barile G R,et al.Diabetic retinopathy:neuron protection as a therapeutic target. Int J Biochem Cell Biol,2013, 45(7): 1525-1529. doi: 10.1016/j.biocel.2013.03.002 pmid: 23506699

[23]	Brownlee M.Biochemistry and molecular cell biology of diabetic complications. Nature,2001, 414(6865): 813-820. doi: 10.1038/414813a pmid: 1174241411742414

[24]	Gabriel R.Neuropeptides and diabetic retinopathy. Br J Clin Pharmacol,2013, 75(5): 1189-1201. doi: 10.1111/bcp.12003 pmid: 3635589

[25]	Giunta S,Castorina A,Bucolo C,et al.Early changes in pituitary adenylate cyclase-activating peptide,vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides,2012, 37(1): 32-39. doi: 10.1016/j.peptides.2012.06.004 pmid: 22721946

[26]	Szabadfi K,Atlasz T,Kiss P,et al.Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res,2012, 348(1): 37-46. doi: 10.1007/s00441-012-1349-0 pmid: 22350850

[27]	Marzagalli R,Scuderi S,Drago F,et al.Emerging role of PACAP as a new potential therapeutic target in major diabetes complications. International Journal of Endocrinology,2015,(2015): 1-11. doi: 10.1155/2015/160928 pmid: 26074958

[28]	Szabadfi K,Szabo A,Kiss P,et al.PACAP promotes neuron survival in early experimental diabetic retinopathy. Neurochem Int,2014, 64(1): 84-91. doi: 10.1016/j.neuint.2013.11.005 pmid: 24262293

[29]	Seaborn T,Masmoudi-Kouli O,Fournier A,et al.Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr Pharm Des,2011, 17(3): 204-214. doi: 10.2174/138161211795049679 pmid: 21348830

[30]	Scuderi S,D’Amico AG,Castorina A,et al. Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides,2013, 39(1): 119-124. doi: 10.1016/j.peptides.2012.11.015 pmid: 23220033

[31]	Gnudi L.Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol Dial Transplant,2012, 27(7): 2642-2649. doi: 10.1093/ndt/gfs121 pmid: 22584788

[32]	Banki E,Kovacs K,Nagy D,et al.Molecular mechanisms underlying the Nephroprotective effects of PACAP in diabetes. J Mol Neurosci,2014, 54(3): 300-309. doi: 10.1007/s12031-014-0249-z pmid: 24535559

[33]	Reglodi D,Kiss P,Horvath G,et al.Effects of pituitary adenylate cyclase activating polypeptide in the urinary system,with special emphasis on its protective effects in the kidney. Neuropeptides,2012, 46(2): 61-70. doi: 10.1016/j.npep.2011.05.001 pmid: 21621841

[34]	Banki E,Degrell P,Kiss P,et al.Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides,2013, 42(4): 125-130. doi: 10.1016/j.peptides.2013.02.002 pmid: 23416022

[35]	Calcutt N A,Cooper M E,Kern T S,et al.Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov,2009, 8(5): 417-429. doi: 10.1038/nrd2476 pmid: 19404313

[36]	Ma Y,Fang S X,Zhao S J,et al.A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. Biomaterials,2015, 51(5): 80-90. doi: 10.1016/j.biomaterials.2015.01.064 pmid: 25771000

[37]	Yu R J,Wang J J,Li J,et al.A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes. Peptides,2010, 31(6): 1062-1067. doi: 10.1016/j.peptides.2010.03.008 pmid: 20307608

[38]	Cheng H H,Ding Y,Yu R R,et al.Neuroprotection of a novel cyclopeptide CHSDGIC from the cyclization of PACAP (1-5) in cellular and rodent models of retinal ganglion cell apoptosis. PLoS One,2014, 9(10): e108090. doi: 10.1371/journal.pone.0108090 pmid: 4186886

[1]	CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.

[2]	SUN Yi-ping, WANG Yue, JIN Zhen, WANG Xiao-yan, SUN Lei, ZHANG Xuan, FENG Chong, ZHOU Xiao-hua. *Establishment and Phenotype Analysis of SHBG* Knockout Mouse Model**[J]. China Biotechnology, 2017, 37(8): 39-45.

[3]	WANG Dong-Bo, MA Yi, WANG Xiao-Li, ZHAO Shao-Jun, HAN Lei, HONG An. Preparation of Recombinant PACAP 27-derived Peptide RP2 and Its Effects on Promoting Corneal Epithelial Cell Proliferation[J]. China Biotechnology, 2015, 35(3): 61-65.

[4]	YUAN Feng-shan, WANG Chang-jun, DONG Fei, ZHAO Yu-hang. The Therapeutic Effect of the Induced Insulin Secreting Cells on Rat Diabetes[J]. China Biotechnology, 2011, 31(5): 94-98.

[5]	. The Therapeutic Effect of the Induced Insulin Secreting Cells on Rat Diabetes[J]. China Biotechnology, 2011, 31(05): 0-0.

[6]	LIU Yan-jie, JI Hong, LIN Lu-xia, ZANG Xue-zhang, SONG Chang-zheng, RONG Hai-qin. Solid Phase Peptide Synthesis and Analysis for Exendin-4[J]. China Biotechnology, 2011, 31(02): 69-73.

[7]	SONG Wen-Cheng, JIN Meng-Fei, LI Dong-Jing, DIAO Li-Fen, ZHANG Hong-Dan, HUANG Jing, TUN Zi-Rong. Cloning, Expression, Purification and Its Biological Activity Study of a Novel GIP Analog[J]. China Biotechnology, 2010, 30(06): 38-43.

[8]	HONG Xiang- Ma-Meng-Gao- Feng-Shen- Tun-Xie-Lin- Zhang-Xu-Ying- Jin-Meng-Fei- Huang-Jing- Tun-Zi-Rong. Expression and Activity of Recombinant Human Glutamate Decarboxylase 65[J]. China Biotechnology, 2009, 29(04): 12-16.

[9]	. Glucagon-Like PeptideⅠand targeted differentiation of stem cells[J]. China Biotechnology, 2007, 27(4): 115-119.

[10]	. Inducing of insulin producing like cell with bone marrow-derived mesenchymal stem cell[J]. China Biotechnology, 2006, 26(0): 230-233.

Viewed

Full text

Abstract

Cited

Shared

Discussed